Phase 4Completed
Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure
A Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Effect of 52 Weeks Treatment With Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure
- Sponsor
- Novartis Pharmaceuticals (Industry)
- Enrollment
- 798 enrolled
- Conditions
- Congestive Heart Failure; Type II Diabetes Mellitus
- Interventions
- vildagliptin; placebo of vildagliptin
- Ages
- adults, older adults
- Registry
- NCT00894868, EUCTR2008-005012-41
Full record on ClinicalTrials.gov
From the registry
This study will assess the effect of vildagliptin on left ventricular function in patients with type 2 diabetes and congestive heart failure (NYHA Class I-III). Effect on HbA1c and overall safety and tolerability will also be assessed.
Primary outcomes
- To evaluate the effect of vildagliptin on left ventricular function in patients with T2DM and CHF (NYHA class I-III) by showing that vildagliptin is at least not inferior to placebo with respect to change in left ventricular ejection fraction (LVEF).
History
Last registry update
Primary completion
Started
Registered